SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer by ANSM
We are excited to announce that SynCore Biotechnology receives [...]
SynCore Bio SB04 Dry-AMD in Phase II/III trial
SB04 is an invasive treatment for dry Age-related Macular [...]
SynCore Biotechnology Receives Investigational New Drug (IND) Clearance of SB05 PC by the Taiwan Food and Drug Administration (TFDA) to Conduct a Phase III Clinical Trial for the Treatment of Metastatic Adenocarcinoma of the Pancreas
Investigational New Drug (IND) clearance from TFDA represents a [...]
SynCore Bio to present the Phase I study of SB01 at ASCO 2017
SynCore Biotechnology Co., Ltd. (SynCore) is selected to present [...]
SynCore Biotechnology Receives Investigational New Drug (IND) Clearance of SB05 PC by the US Food and Drug Administration (FDA) to Conduct a Phase III Clinical Trial for the Treatment of Metastatic Adenocarcinoma of the Pancreas
• Investigational New Drug (IND) clearance from US FDA [...]
SynCoreBio Signs Contract with Swiss Company Y-YBar To Jointly Develop Precision Instruments for the Diagnosis of Eye Diseases
SynCore Biotechnology Co. Ltd. (4192) signed a global contract [...]
SynCoreBio significance progress in the negotiations of cooperation strategy. Breakthrough the predominance and maximizing the value of technology platform!
SynCoreBio together with its strategic partner German company Medigene [...]